Leuprorelin 1-Month Depot as Neoadjuvant Therapy for Prostate Cancer
Domenico Prezioso(Federico II University Hospital), on behalf of Takeda NHT Italian Group, Rodolfo Montironi(Marche Polytechnic University), T. Lotti(University of Naples Federico II), Mario Polito(Federico II University Hospital)
Cited by 1
Related Papers
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
|Cancers|2021|289
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
|Cells|2020|256
The World Health Organization 2016 classification of testicular non‐germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel
|Histopathology|2016|236
Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group
|Archivio Italiano di Urologia e Andrologia|2015|202